Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-11-01 / Am J Cancer Res 2019;9(11):2456-2468Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-10-24 / Immunology 2020 01;159(1):75-87Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-10-17 / Pathol. Res. Pract. 2019 Dec;215(12):152691Immunotherapy Based on Dendritic Cell-Targeted/-Derived Extracellular Vesicles-A Novel Strategy for Enhancement of the Anti-tumor Immune Response
/in Dendritic Cells, International Publications /von 2019-10-11 / Front Pharmacol 2019;10:1152Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-11 / Biomedicines 2019 Oct;7(4)Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-09 / Front Immunol 2019;10:2353Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2019-10-03 / Cancers (Basel) 2019 Oct;11(10)Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-09-19 / Cancers (Basel) 2019 Sep;11(9)IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de